

„Publikationsliste original 01.09.2022 bis 31.08.2023“

1. [Treatment Algorithm for Patients With Gastric Adenocarcinoma: Austrian Consensus on Systemic Therapy - An Update.](#) Wöll E, Amann A, Eisterer W, Gerger A, Grünberger B, Rumpold H, Weiss L, Winder T, Greil R, Prager GW. *Anticancer Res.* 2023 Jul;43(7):2889-2897. doi: 10.21873/anticancer.16460.PMID: 37351962 Review.

2.435

2. [Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission.](#) Gamerith G, Mildner F, Merkel PA, Harris K, Cooney L, Lim N, Spiera R, Seo P, Langford CA, Hoffman GS, St Clair EW, Fervenza FC, Monach P, Ytterberg SR, Geetha D, Amann A, Wolf D, Specks U, Stone JH, Kronbichler A. *Ann Rheum Dis.* 2023 Feb;82(2):253-261. doi: 10.1136/ard-2022-222479. Epub 2022 Aug 16.PMID: 35973802 Clinical Trial.

28.003

3. [Molecular Characteristics of Radon Associated Lung Cancer Highlights MET Alterations.](#) Gamerith G, Kloppenburg M, Mildner F, Amann A, Merkelbach-Bruse S, Heydt C, Siemanowski J, Buettner R, Fiegl M, Manzl C, Pall G. *Cancers (Basel).* 2022 Oct 19;14(20):5113. doi: 10.3390/cancers14205113.PMID: 36291897

6.575

4. [PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system.](#) Zimmer K, Kocher F, Untergasser G, Kircher B, Amann A, Baca Y, Xiu J, Korn WM, Berger MD, Lenz HJ, Puccini A, Fontana E, Shields AF, Marshall JL, Hall M, El-Deiry WS, Hsiehchen D, Macarulla T, Tabernero J, Pichler R, Khushman M, Manne U, Lou E, Wolf D, Sokolova V, Schnaiter S, Zeimet AG, Gulhati P, Widmann G, Seeber A. *NPJ Precis Oncol.* 2023 Jul 3;7(1):64. doi: 10.1038/s41698-023-00409-5.PMID: 37400502

10.123

5. [LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases-a phase II study.](#) Piringer G, Gruenberger T, Thaler J, Kühner I, Kaczirek K, Längle F, Viragos-Toth I, Amann A, Eisterer W, Függer R, Andel J, Pichler A, Stiff J, Sölkner L, Gnant M, Öfner D. *Front Oncol.* 2023 Aug 9;13:1231600. doi: 10.3389/fonc.2023.1231600. eCollection 2023.PMID: 37621684

5.738

6. [A cellular hierarchy in melanoma uncouples growth and metastasis.](#) Karras P, Bordeu I, Pozniak J, Nowosad A, Pazzi C, Van Raemdonck N, Landeloos E, Van Herck Y, Pedri D, Bervoets G, Makhzami S, Khoo JH, Pavie B, Lamote J, Marin-Bejar O, Dewaele M, Liang H, Zhang X, Hua Y, Wouters J, Browaeys R, Bergers G, Saeys Y, Bosisio F, van den Oord J, Lambrechts D, Rustgi AK, **Bechter O**, Blanpain C, Simons BD, Rambow F, Marine JC. *Nature*. 2022 Oct;610(7930):190-198. doi: 10.1038/s41586-022-05242-7. Epub 2022 Sep 21. PMID: 36131018

87.244

7. [CD4⁺ T cell-induced inflammatory cell death controls immune-evasive tumours.](#) Kruse B, Buzzai AC, Shridhar N, Braun AD, Gellert S, Knauth K, Pozniak J, Peters J, Dittmann P, Mengoni M, van der Sluis TC, Höhn S, Antoranz A, Krone A, Fu Y, Yu D, Essand M, Geffers R, Mougiakakos D, Kahlfuß S, Kashkar H, Gaffal E, Bosisio FM, **Bechter O**, Rambow F, Marine JC, Kastenmüller W, Müller AJ, Tüting T. *Nature*. 2023 Jun;618(7967):1033-1040. doi: 10.1038/s41586-023-06199-x. Epub 2023 Jun 14. PMID: 37316667

87.244

8. [The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity.](#) Ho P, Melms JC, Rogava M, Frangieh CJ, Poźniak J, Shah SB, Walsh Z, Kyrysyuk O, Amin AD, Caprio L, Fullerton BT, Soni RK, Ager CR, Biermann J, Wang Y, Khosravi-Maharlooei M, Zanetti G, Mu M, Fatima H, Moore EK, Vasan N, Bakhoun SF, Reiner SL, Bernatchez C, Sykes M, Mace EM, Wucherpfeinig KW, Schadendorf D, **Bechter O**, Shah P, Schwartz GK, Marine JC, Izar B. *Cancer Cell*. 2023 Jul 10;41(7):1207-1221.e12. doi: 10.1016/j.ccell.2023.05.014. Epub 2023 Jun 15. PMID: 37327789

38.585

9. [Multiomics and spatial mapping characterizes human CD8⁺ T cell states in cancer.](#) Naulaerts S, Datsi A, Borrás DM, Antoranz Martínez A, Messiaen J, Vanmeerbeek I, Sprooten J, Laureano RS, Govaerts J, Panovska D, Derweduwe M, Sabel MC, Rapp M, Ni W, Mackay S, Van Herck Y, Gelens L, Venken T, More S, **Bechter O**, Bergers G, Liston A, De Vleeschouwer S, Van Den Eynde BJ, Lambrechts D, Verfaillie M, Bosisio F, Tejpar S, Borst J, Sorg RV, De Smet F, Garg AD. *Sci Transl Med*. 2023 Apr 12;15(691):eadd1016. doi: 10.1126/scitranslmed.add1016. Epub 2023 Apr 12. PMID: 37043555

19.343

10. [Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors.](#) Laenens D, Yu Y, Santens B, Jacobs J, Beuselinck B, **Bechter O**, Wauters E, Staessen J, Janssens S, Van Aelst L. *J Clin Oncol*. 2022 Oct 10;40(29):3430-3438. doi: 10.1200/JCO.21.01808. Epub 2022 Jun 30. PMID: 35772044

50.739

11. [Melanoma cell plasticity poses diagnostic challenges: a case series.](#) Mennens F, Van Herck Y, Sciot R, Vanden Bempt I, Boecxstaens V, Garmyn M, **Bechter O**. *Melanoma Res.* 2022 Dec 1;32(6):428-439. doi: 10.1097/CMR.0000000000000852. Epub 2022 Sep 20. PMID: 36125893

3.199

12. [Mapping the Immune Landscape in Metastatic Melanoma Reveals Localized Cell-Cell Interactions That Predict Immunotherapy Response.](#) Antoranz A, Van Herck Y, Bolognesi MM, Lynch SM, Rahman A, Gallagher WM, Boecxstaens V, Marine JC, Cattoretti G, van den Oord JJ, De Smet F, **Bechter O**, Bosisio FM. *Cancer Res.* 2022 Sep 16;82(18):3275-3290. doi: 10.1158/0008-5472.CAN-22-0363. PMID: 35834277

13.312

13. [Role of immune checkpoint inhibitors in metastatic uveal melanoma: a single-center retrospective cohort study.](#) Vanaken L, Woei-A-Jin FJSH, Van Ginderdeuren R, Deroose CM, Laenen A, Missotten G, Thal DR, **Bechter O**, Schöffski P, Clement P. *Acta Oncol.* 2023 May;62(5):480-487. doi: 10.1080/0284186X.2023.2211206. Epub 2023 May 18. PMID: 37200223

4.311

14. [Publisher Correction: Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy.](#) Vanmeerbeek I, Borrás DM, Sprooten J, **Bechter O**, Tejpar S, Garg AD. *Genes Immun.* 2022 Dec;23(8):260. doi: 10.1038/s41435-022-00189-1. PMID: 36456662 No abstract available.

4.248

15. [SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response.](#) Ibáñez-Molero S, van Vliet A, Pozniak J, Hummelink K, Terry AM, Monkhorst K, Sanders J, Hofland I, Landeloos E, Van Herck Y, **Bechter O**, Kuilman T, Zhong W, Marine JC, Wessels L, Peeper DS. *Oncoimmunology.* 2022 Nov 29;11(1):2139074. doi: 10.1080/2162402X.2022.2139074. eCollection 2022. PMID: 36465485

7.723

16. [Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy.](#) Talebi A, de Laat V, Spotbeen X, Dehairs J, Rambow F, Rogiers A, Vanderhoydonc F, Rizotto L, Planque M, Doglioni G, Motamedi S, Nittner D, Roskams T, Agostinis P, **Bechter O**, Boecxstaens V, Garmyn M, O'Farrell M, Wagman A, Kemble G, Leucci E, Fendt SM, Marine JC, Swinnen JV. *J Exp Clin Cancer Res.* 2023 Apr 19;42(1):92. doi: 10.1186/s13046-023-02664-7. PMID: 37072838

12.658

17. [Retrospective Analysis of Treatment Pathways in Patients With BRAF^{V600E}-mutant Metastatic Colorectal Carcinoma - MORSE^{CRC}](#). Gerger A, **Eisterer W**, Fuxius S, Bastian S, Koeberle D, Welslau M, Sanoyan DA, Maas C, Uhlig J, Fenchel K, Greil R, VON DER Heyde E, Agocs GR, Weide R, Schwager M, Reichenbach F, Modest DP, Fritsch R. *Anticancer Res.* 2022 Oct;42(10):4773-4785. doi: 10.21873/anticancerres.15982.PMID: 36191968
- 2.435**
18. [New entity of microsecretory adenocarcinoma of salivary glands: first case with recurrence and metastases - proof of malignancy](#). Jurmeister P, Haas C, **Eisterer W**, Rogatsch H, Ihrler S. *Virchows Arch.* 2022 Dec;481(6):963-965. doi: 10.1007/s00428-022-03374-9. Epub 2022 Jul 2.PMID: 35780228
- 4.548**
19. [Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial](#). Panje C, Hayoz S, **Eisterer W**, Hess V, Thuss-Patience P, Schacher S, Dürr D, Wagner AD, Girschikofsky M, Eboulet E, Stahl M, Ruhstaller T. *Eur J Cancer.* 2022 Dec;177:186-193. doi: 10.1016/j.ejca.2022.09.035. Epub 2022 Oct 5.PMID: 36368252 Clinical Trial.
- 10.002**
20. [Amp\(1q\) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma](#). Locher M, Jukic E, Vogl V, Keller MA, Kröll T, Schwendinger S, Oberhuber K, Verdorfer I, Mühlegger BE, Witsch-Baumgartner M, Nachbaur D, Willenbacher W, **Gunsilius E**, Wolf D, Zschocke J, Steiner N. *Eur J Haematol.* 2023 Mar;110(3):296-304. doi: 10.1111/ejh.13905. Epub 2022 Dec 4.PMID: 36433728
- 3.674**
21. [Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies](#). Schiller GJ, Lipe BC, Bahlis NJ, Tuchman SA, Bensinger WI, Sutherland HJ, Lentzsch S, Baljevic M, White D, Kotb R, Chen CI, Rossi A, Biran N, LeBlanc R, Grosicki S, Martelli M, **Gunsilius E**, Špička I, Stevens DA, Facon T, Mesa MG, Zhang C, Van Domelen DR, Bentur OS, Gasparetto C. *Clin Lymphoma Myeloma Leuk.* 2023 Sep;23(9):e286-e296.e4. doi: 10.1016/j.clml.2023.06.001. Epub 2023 Jun 5.PMID: 37393120
- 2.822**
22. [Autologous and Allogeneic Stem Cell Transplantation as Salvage Treatment Options for Relapsed/Refractory Multiple Myeloma: A Single-center Experience over 20 Years](#). Steiner N, Schober P, Willenbacher W, Kircher B, **Gunsilius E**, Wolf D, Nachbaur D. *Anticancer Res.* 2022 Dec;42(12):5825-5832. doi: 10.21873/anticancerres.16090.PMID: 36456157
- 2.435**

23. [Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational Study.](#) Steiner N, Göbel G, Mauser L, Mühlwinkel L, Fischinger M, Künz T, Willenbacher W, Hetzenauer G, Rudzki J, Nussbaumer W, Mayer W, **Gunsilius E**, Kircher B, Wolf D, Nachbaur D. *Cancers (Basel)*. 2023 Jan 18;15(3):608. doi: 10.3390/cancers15030608. PMID: 36765566

6.575

24. [Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets.](#) Kocher F, Puccini A, Untergasser G, Martowicz A, Zimmer K, **Pircher A**, Baca Y, Xiu J, Haybaeck J, Tymoszuk P, Goldberg RM, Petrillo A, Shields AF, Salem ME, Marshall JL, Hall M, Korn WM, Nabhan C, Battaglin F, Lenz HJ, Lou E, Choo SP, Toh CK, Gasteiger S, Pichler R, Wolf D, Seeber A. *Clin Cancer Res*. 2022 Nov 14;28(22):4957-4967. doi: 10.1158/1078-0432.CCR-22-0275. PMID: 36112544

13.801

25. [Optimization of postoperative surveillance protocols in upper tract urothelial cancer: A retrospective cohort study.](#) Lindner AK, Pichler M, Maier S, Ulmer H, Gorreri T, Luger AK, Barth DA, Seeber A, **Kocher F**, Pichler R. *Front Oncol*. 2023 Mar 14;13:1143030. doi: 10.3389/fonc.2023.1143030. eCollection 2023. PMID: 36998439

5.738

26. [A chemokine network of T cell exhaustion and metabolic reprogramming in renal cell carcinoma.](#) Pichler R, Siska PJ, Tymoszuk P, Martowicz A, Untergasser G, Mayr R, Weber F, Seeber A, **Kocher F**, Barth DA, Pichler M, Thurnher M. *Front Immunol*. 2023 Mar 16;14:1095195. doi: 10.3389/fimmu.2023.1095195. eCollection 2023. PMID: 37006314

8.787

27. [Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy.](#) Lindner AK, Lackner F, Tymoszuk P, Barth DA, Seeber A, **Kocher F**, Toth B, Hochleitner M, Pichler M, Pichler R. *Biol Sex Differ*. 2023 Jun 5;14(1):38. doi: 10.1186/s13293-023-00522-x. PMID: 37277835

8.811

28. [CXCR3 Expression Is Associated with Advanced Tumor Stage and Grade Influencing Survival after Surgery of Localised Renal Cell Carcinoma.](#) Lindner AK, Martowicz A, Untergasser G, Haybaeck J, Compérat E, **Kocher F**, Seeber A, Thurnher M, Pichler R. *Cancers (Basel)*. 2023 Feb 4;15(4):1001. doi: 10.3390/cancers15041001. PMID: 36831346

6.575

29. [Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAF^{V600E} mutated, microsatellite-stable colon cancer: A case report and literature review](#) Gudrun Piringer, Jörn Decker, Vera Trommet, **Thomas Kühr**, Sonja Heibl, Konrad Dörfler, **Josef Thaler**-Affiliations expand; PMID: 37213293
- 5.738
30. [High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer.](#) Salcher S, Sturm G, Horvath L, Untergasser G, Kuempers C, Fotakis G, Panizzolo E, Martowicz A, Trebo M, **Pall G**, Gamerith G, Sykora M, Augustin F, Schmitz K, Finotello F, Rieder D, Perner S, Sopper S, Wolf D, **Pircher A**, Trajanoski Z. *Cancer Cell*. 2022 Dec 12;40(12):1503-1520.e8. doi: 10.1016/j.ccell.2022.10.008. Epub 2022 Nov 10. PMID: 36368318
- 38.585
31. [Molecular Characteristics of Radon Associated Lung Cancer Highlights MET Alterations.](#) Gamerith G, Kloppenburg M, Mildner F, Amann A, Merkelbach-Bruse S, Heydt C, Siemanowski J, Buettner R, Fiegl M, Manzl C, **Pall G**. *Cancers (Basel)*. 2022 Oct 19;14(20):5113. doi: 10.3390/cancers14205113. PMID: 36291897
- 6.575
32. [Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer.](#) Wagner SM, Magnes T, Melchardt T, Kiem D, Weiss L, Neureiter D, Wagner C, Aretin MB, Nemeč S, Gamerith G, **Pall G**, Greil R, Fueterer T. *Anticancer Res*. 2023 Mar;43(3):1273-1282. doi: 10.21873/anticancer.16274. PMID: 36854497
- 2.435
33. [Compartmentalization of the host microbiome: how tumor microbiota shapes checkpoint immunotherapy outcome and offers therapeutic prospects.](#) Boesch M, Horvath L, Baty F, **Pircher A**, Wolf D, Spahn S, Straussman R, Tilg H, Brutsche MH. *J Immunother Cancer*. 2022 Nov;10(11):e005401. doi: 10.1136/jitc-2022-005401. PMID: 36343977
- 12.485
34. [Tissue iron distribution in patients with anemia of inflammation: Results of a pilot study.](#) Lanser L, Plaikner M, Schroll A, Burkert FR, Seiwald S, Fauser J, Petzer V, Bellmann-Weiler R, Fritsche G, Tancevski I, Duftner C, **Pircher A**, Seeber A, Zoller H, Kremser C, Henninger B, Weiss G. *Am J Hematol*. 2023 Jun;98(6):890-899. doi: 10.1002/ajh.26909. Epub 2023 Mar 15. PMID: 36880875
- 13.268

35. [Pembrolizumab in mCRPC - Combination therapies as breakthrough to success?](#) Plas S, Pircher A, Heidegger I. *Curr Opin Urol.* 2023 Aug 22. doi: 10.1097/MOU.0000000000001121. Online ahead of print.PMID: 37603022

2.808

36. [Differential diagnoses and the mutational landscape of myelodysplastic/myeloproliferative neoplasm with neutrophilia: A case report.](#) Strasser B, Grünberger M, Steindl R, Heibl S, Thaler J, Haushofer A. *Mol Clin Oncol.* 2023 Jun 28;19(2):62. doi: 10.3892/mco.2023.2658. eCollection 2023 Aug.PMID: 37456801

0.393

37. [Austrian Society for Hematology and Medical Oncology \(OeGHO\) spring meeting 2023.](#) Wöll E. *Memo.* 2023;16(1):3. doi: 10.1007/s12254-022-00865-y. Epub 2023 Feb 21.PMID: 36844901 No abstract available.

0.209

38. [Pulmonary recovery from COVID-19 in patients with metabolic diseases: a longitudinal prospective cohort study.](#) Sonnweber T, Grubwieser P, Pizzini A, Boehm A, Sahanic S, Luger A, Schwabl C, Widmann G, Egger A, Hoermann G, Wöll E, Puchner B, Kaser S, Theurl I, Nairiz M, Tymoszuk P, Weiss G, Joannidis M, Löffler-Ragg J, Tancevski I. *Sci Rep.* 2023 Feb 14;13(1):2599. doi: 10.1038/s41598-023-29654-1.PMID: 36788324

4.997

39. [Stroke Care Pathway ensures high-quality stroke management in the COVID-19 pandemic.](#) Mayer-Suess L, Ter Telgte A, Praxmarer S, Willeit J, Wöll E, Geley T, Rinner H, Knoflach M, Kiechl S; Tyrolean Stroke Pathway Group. *Sci Rep.* 2023 Apr 5;13(1):5587. doi: 10.1038/s41598-023-32586-5.PMID: 37019970

4.997

40. ["Beyond the guidelines" - Deviations in adherence to infection control measures in Tyrolean hospitals, Austria.](#) Berkold M, Fuchs S, Kuppelwieser B, Ulmer H, Kettner M, Thummer L, Wöll E, Lass-Flörl C; Study Group Hygiene Tyrol. *Am J Infect Control.* 2023 Apr;51(4):406-412. doi: 10.1016/j.ajic.2022.07.005. Epub 2022 Jul 20.PMID: 35870661

4.9

41. [COVID-19 and its continuing burden after 12 months: a longitudinal observational prospective multicentre trial](#). Sahanic S, Tymoszuk P, Luger AK, Hufner K, Boehm A, Pizzini A, Schwabl C, Koppelstätter S, Kurz K, Asshoff M, Mosheimer-Feistritzer B, Coen M, Pfeifer B, Rass V, Egger A, Hörmann G, Sperner-Unterweger B, Helbok R, **Wöll E**, Weiss G, Widmann G, Tancevski I, Sonnweber T, Löffler-Ragg J. *ERJ Open Res.* 2023 Mar 13;9(2):00317-2022. doi: 10.1183/23120541.00317-2022. eCollection 2023 Mar. PMID: 36960350

4.239

42. [Persistent somatic symptoms are key to individual illness perception at one year after COVID-19 in a cross-sectional analysis of a prospective cohort study](#). Hufner K, Tymoszuk P, Sahanic S, Luger A, Boehm A, Pizzini A, Schwabl C, Koppelstätter S, Kurz K, Asshoff M, Mosheimer-Feistritzer B, Pfeifer B, Rass V, Schroll A, Iglseder S, Egger A, **Wöll E**, Weiss G, Helbok R, Widmann G, Sonnweber T, Tancevski I, Sperner-Unterweger B, Löffler-Ragg J. *J Psychosom Res.* 2023 Jun;169:111234. doi: 10.1016/j.jpsychores.2023.111234. Epub 2023 Mar 17. PMID: 36965396

4.62

Gesamtpunkte: 563.932